Genentech, Inc.
About Genentech, Inc.
1691 articles about Genentech, Inc.
-
Data from the OCARINA II trial shows that a 10-minute subcutaneous injection of Ocrevus achieves similar pharmacokinetics as the typical hours-long intravenous infusion in multiple sclerosis patients.
-
Four-Year Follow-Up Data for Genentech’s Evrysdi Show Continued Increase in Number of Children With a Severe Form of Spinal Muscular Atrophy (SMA) Able to Sit, Stand and Walk
6/30/2023
Genentech, a member of the Roche Group, announced new long-term data for Evrysdi® from the open-label extension of the pivotal FIREFISH study, reinforcing its sustained efficacy and safety profile in children with Type 1 spinal muscular atrophy.
-
FDA Approves Genentech’s Columvi, the First and Only Bispecific Antibody With a Fixed-Duration Treatment for People With Relapsed or Refractory Diffuse Large B-cell Lymphoma
6/16/2023
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has approved Columvi® for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma not otherwise specified or large B-cell lymphoma arising from follicular lymphoma, after two or more lines of systemic therapy.
-
With Roche’s FDA approval on Thursday, both companies' bispecific antibodies will hit the market this summer for relapsed or refractory diffuse large B-cell lymphoma.
-
New Data Show Genentech’s Subcutaneously Administered Crovalimab Achieved Disease Control and Was Well-Tolerated in People With Paroxysmal Nocturnal Hemoglobinuria (PNH)
6/9/2023
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that positive results from the global Phase III COMMODORE 1 and 2 studies, evaluating the efficacy and safety of crovalimab, an investigational, novel anti-C5 recycling monoclonal antibody, compared to eculizumab.
-
Biosimilars effectively lowered cancer therapy Herceptin prices and made trastuzumab more accessible to patients, finds a new study from the USC Schaeffer Center.
-
Genentech’s BTK Inhibitor Fenebrutinib Significantly Reduced Brain Lesions in People With Relapsing Forms of Multiple Sclerosis
5/17/2023
Genentech, a member of the Roche Group, announced positive results from the Phase II FENopta study evaluating investigational oral fenebrutinib in adults with relapsing forms of multiple sclerosis.
-
Fenebrutinib in a mid-phase trial reduced brain legions in relapsing forms of multiple sclerosis, the company reported. It is the only reversible BTK inhibitor currently in Phase III MS trials.
-
FDA Accepts Application for Genentech’s Vabysmo for the Treatment of Retinal Vein Occlusion (RVO)
5/9/2023
Genentech, a member of the Roche Group, announced that the U.S. Food and Drug Administration has accepted the company’s supplemental Biologics License Application for Vabysmo® for the treatment of macular edema following retinal vein occlusion.
-
New Vabysmo Data Suggest Greater Retinal Drying Versus Aflibercept in Wet Age-Related Macular Degeneration and Diabetic Macular Edema
4/25/2023
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced that post-hoc data indicate treatment with Vabysmo® (faricimab-svoa) led to greater and faster drying of retinal fluid with fewer injections compared to aflibercept in wet, or neovascular, age-related macular degeneration (AMD).
-
Genentech Announces Industry-Leading Brain Health Research Collaborations and Latest Data Across Neuroscience Medicines at AAN 2023 Annual Meeting
4/24/2023
–– Roche, Genentech and partners embark on global prevalence research, trend-spotting with digital analysis, and telehealth initiatives to assess & address deterrents to brain health to better understand holistic health journeys of patients with neurologic diseases.
-
Polivy is approved for front-line DLBCL as part of a combination regimen including Rituxan, cyclophosphamide, doxorubicin and prednisone.
-
FDA Approves Genentech’s Polivy in Combination With R-CHP for People With Certain Types of Previously Untreated Diffuse Large B-cell Lymphoma
4/19/2023
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that the U.S. Food and Drug Administration (FDA) has approved Polivy® (polatuzumab vedotin-piiq) in combination with Rituxan® (rituximab).
-
Roche, AstraZeneca, Moderna, Merck and Affimed presented new data in liver cancer, lung cancer, melanoma and lymphoma.
-
Genentech’s Tecentriq Plus Avastin Reduced the Risk of Cancer Returning in People With Certain Types of Adjuvant Liver Cancer in a Phase III Study
4/16/2023
Genentech, a member of the Roche Group, announced new data from the Phase III IMbrave050 study that show Tecentriq® plus Avastin® demonstrated a statistically significant improvement in recurrence-free survival in people with hepatocellular carcinoma at high risk of disease recurrence following liver resection or ablation with curative intent.
-
Genentech Data Highlights Strength of Ophthalmology Portfolio and Commitment to Advancing Eye Care at ARVO 2023
4/13/2023
Genentech, a member of the Roche Group, announced that new data for its approved and investigational medicines will be highlighted in 30 abstracts at the 2023 Association for Research in Vision and Ophthalmology Annual Meeting, which will be held from April 23-27 in New Orleans, LA.
-
Top Biotech Licensing Deals of Q1 2023
3/30/2023
There have already been several big biotech licensing deals in Q1. See inside for some of this quarter's biggest licensing deals — from the surprising and pivotal to the lucrative and consequential. -
The FDA is expected to make decisions on Emergent BioSolutions' sNDA for OTC Narcan and Roche's Polivy in frontline DLBCL.
-
The American Diabetes Association and Genentech Partner to Increase Equitable Access to Eye Health Care
3/20/2023
The American Diabetes Association® and Genentech, a member of the Roche Group, announced a new partnership as part of the ADA's Health Equity Now work to tackle access to screening and treatment for eye diseases that affect the diabetes community.
-
An independent panel of advisers voted to approve Genentech's Polivy after internal FDA staff raised concerns regarding the efficacy and risk-benefit profile as a first-line treatment for large B-cell lymphoma.